Webcast Alert: ADVENTRX Pharmaceuticals, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation
NEW YORK, July 14 /PRNewswire-FirstCall/ — ADVENTRX Pharmaceuticals, Inc. (ANX) announces the following Webcast:
LHA Life Sciences & Med Tech Day 2010 What: Presentation When: July 20, 2010 @ 10:00 AM Eastern http://www.investorcalendar.com/ Where: ClientPage.asp?ID=160318 Live over the Internet --Simply log on to the How: web at the address above. Contact: Cheryl Palazzo, 212-838-3777, firstname.lastname@example.org
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=160318 or http://www.investorcalendar.com/
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) is a specialty pharmaceutical company whose product candidates are designed to improve upon existing cancer treatments by addressing limitations associated with their safety and use. Its lead product candidates include ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (NavelbineÂ®), to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of the chemotherapy drug docetaxel (TaxotereÂ®) for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The Company expects to file an NDA for ANX-530 in the fourth quarter of 2010. Additional information regarding ADVENTRX is available at www.adventrx.com
SOURCE ADVENTRX Pharmaceuticals, Inc.